In agreement with the above data that SRSF10 acted as an HCC promoter, we found markedly larger tumor volumes accompanied by increased CDC25A and shrinking p-CDC25A(S178), and depletion of both CDC25A (△E6) and CDC25A (FL) effectively counteracted the promotion of tumorigenic ability in the presence of SRSF10, as anticipated (Fig. 8A and B). The gene discussed is SRSF10; the disease is neoplasm.